Last updated: February 12, 2024
Sponsor: Berkeley Eye Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Visual Acuity
Quality of Vision After Surgery (QUVID) Questionnaire
Defocus Curve
Clinical Study ID
NCT06064916
69865263
Ages > 40 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adults, 40 years of age having already undergone cataract removal byphacoemulsification with a clear corneal incision in both eyes with implantation ofthe Vivity IOL (DAT***/CCWET*)
- Prior uncomplicated, distance-targeted, bilateral myopic LASIK or PRK (photorefractivekeratectomy) surgery and corneal spherical aberration greater than ≥0.30 μ and ≤ 1.20 μ in at least one eye (6.00 mm) as measured at their cataract pre-op visit
- Able to comprehend and willing to sign informed consent and complete all requiredtesting procedures
- Best Corrected Distance Visual Acuity (BCDVA) projected to be 0.10 logMAR (MinimumAngle of Resolution) or better
- Clear intraocular media
- Minimum of two weeks post YAG (yttrium aluminum garnet) capsulotomy to treat PCO (posterior capsular opacification)
- Residual refractive astigmatism ≤0.50 diopters
- Post-operative refractive spherical equivalent from +0.50 to -0.50 sphericalequivalent
Exclusion
Exclusion Criteria:
- Any corneal abnormality, other than regular corneal astigmatism or myopic LASIK/PRKsurgery, (as determined by pre-operative testing) that in the opinion of theinvestigator would confound the outcome(s) of the study
- Any complication during cataract surgery (capsular tear, vitrectomy, etc)
- History of or current retinal conditions or predisposition to retinal conditions orpredisposition to retinal conditions
- Amblyopia or strabismus in either eye
- History of or current anterior or posterior segment inflammation of any etiology
- Any form of neovascularization on or within the eye
- Glaucoma (uncontrolled or controlled with medication)
- Optic nerve atrophy
- Subjects with diagnosed degenerative eye disorders
- Postoperative CDVA worse than 0.10 logMAR in either eye.
- Subjects who have an acute or chronic disease or illness that would confound theresults of this investigation in the opinion of the principal investigator (e.g.immunocompromised, connective tissue disease, clinically significant atopic disease,etc)
Study Design
Total Participants: 40
Treatment Group(s): 6
Primary Treatment: Visual Acuity
Phase:
Study Start date:
July 25, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Berkeley Eye Center
Houston, Texas 77027
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.